Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meningococcal B Vaccine Schedule Study in Adolescents
NCT00137917Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2002
- Primary completion
- Jun 2003
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, single-blind trial of meningococcal group B multicomponent recombinant vaccine in Meningococcal serogroup B infection (MenB) (3 arms), sponsored by GSK. Primary endpoint: Meningococcal serogroup B immune response (4-fold increase in SBA). Started Jul 2002; status: completed.
02
Drugs
meningococcal group B multicomponent recombinant vaccine
03
Conditions
Meningococcal serogroup B infection (MenB)
Beyond the preview
Go deeper on NCT00137917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137917.